HEALTHCARE AI

LifeSciBench: A Foundation for Realistic AI Evaluation in Life Sciences

By

–

17 June 2026 22h41

LifeSciBench is a foundation for more realistic evaluation, targeted improvements, and continued partnership with the life sciences community—helping the field measure progress, identify gaps, and improve AI together for the benefit of everyone.

LifeSciBench tests reasoning; GPT‑Rosalind outperforms GPT‑5.5

By

–

17 June 2026 22h41

Benchmarks often test biological knowledge or narrow skills. The tasks in LifeSciBench test whether models can reason from evidence, work with scientific artifacts, handle uncertainty, and make useful decisions under real-world constraints. GPT‑Rosalind scores above GPT‑5.5

OpenAI introduces LifeSciBench benchmark for life science research

By

–

17 June 2026 22h41

Introducing LifeSciBench, a benchmark for measuring and improving how well AI supports real-world life science research. Developed with 173 scientists from biotechnology and pharmaceutical research, LifeSciBench includes 750 expert-authored tasks across seven biological research

→ View original post on X — @gdb

Improving a challenging reaction in medicinal chemistry with GPT-5.4

By

@gdb

–

17 June 2026 22h32

GPT-5.4 for improving a challenging reaction in medicinal chemistry: https://t.co/VqnADd8TP3
— Greg Brockman (@gdb) 17 juin 2026

—
GPT-5.4 for improving a challenging reaction in medicinal chemistry:
—

GPT-5.4 and Maria AI improve drug discovery reaction

By

–

17 June 2026 19h10

GPT-5.4 helped drive a medicinal chemistry project from literature review to a validated experimental result.

Paired with https://t.co/gcDaph8b2B’s Maria AI and specialized lab, the model proposed an unexpected way to improve a widely used reaction in drug discovery. pic.twitter.com/KmyBlHLX8y
— OpenAI (@OpenAI) 17 juin 2026

GPT-5.4 helped drive a medicinal chemistry project from literature review to a validated experimental result. Paired with http://
Molecule.one’s Maria AI and specialized lab, the model proposed an unexpected way to improve a widely used reaction in drug discovery.

→ View original post on X — @erictopol

Medical AI Models for End-to-End Care in ER and Outpatient Visits

By

@erictopol

–

17 June 2026 18h45

Until now, we haven't seen medical AI models intended to provide end-to-end care after presentation to an emergency department or longitudinally via 3 sequential outpatient visits. There's a lot to unpack in 2 new @nature publications today. Summarized in a new post.

→ View original post on X — @jiqizhixin

MMDesign platform generates nanobody candidates from target protein and binding site

By

@jiqizhixin

–

17 June 2026 6h27

What if you could design a new nanobody from scratch with only tens of lab tests instead of millions? MoleculeMind (led by Jinbo Xu) presents MMDesign – a platform that generates and filters nanobody candidates from just a target protein and desired binding site. The system